Solid Biosciences Inc. SLDB Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | —— | —— | —— | ||
| $46.14M+49.3% | $38.14M+23.9% | $38.86M+42.2% | $32.42M+66.6% | $30.91M+63.8% | ||
| $11.17M+22.2% | $11.27M+23.5% | $9.2M+17.1% | $9.28M+11.4% | $9.14M+14.4% | ||
| —— | —— | —— | —— | —— | ||
| $57.31M+43.1% | $49.4M+23.8% | $48.06M+36.6% | $41.69M+50.0% | $40.05M+49.1% | ||
| $57.31M+43.1% | $49.4M+23.8% | $48.06M+36.6% | $41.69M+50.0% | $40.05M+49.1% | ||
| -$57.31M-43.1% | -$49.4M-23.8% | -$48.06M-36.6% | -$41.69M-50.0% | -$40.05M-49.1% | ||
| —— | $0-100% | -$336K-510% | $60K-31.8% | $68K-28.4% | ||
| $2.06M-10.3% | $2.05M+6.6% | $2.59M+11.1% | $2.97M+15.6% | $2.3M-13.2% | ||
| $571K-25.8% | $0— | $2.28M-7.1% | $2.21M-18.5% | $770K-69.9% | ||
| -$1.65M0.0% | -$2.65M-123% | -$850K+28.4% | -$900K+24.2% | -$1.65M-38.9% | ||
| -$56.74M-44.4% | -$49.79M-16.9% | -$45.78M-39.9% | -$39.48M-57.5% | -$39.28M-61.6% | ||
| -$0.52+11.9% | -$0.53+48.0% | -$0.48+39.2% | -$0.42+31.1% | -$0.59+7.8% | ||
| -$0.52+11.9% | -$0.53+48.0% | -$0.48+39.2% | -$0.42+31.1% | -$0.59+7.8% | ||
| 109.8M+65.5% | 87.5M+114% | 94.4M+128% | 94.1M+130% | 66.3M+73.9% | ||
| 109.8M+65.5% | 87.5M+114% | 94.4M+128% | 94.1M+130% | 66.3M+73.9% | ||
| $157K-16.5% | $219K+10.1% | $210K-0.5% | $207K-13.4% | $188K+6,167% | ||
| -$57.31M-43.1% | -$49.4M-23.8% | -$48.06M-36.6% | -$41.69M-50.0% | -$40.05M-49.1% | ||
| -$56.91M-43.6% | -$48.94M-24.2% | -$47.68M-37.1% | -$41.31M-55.6% | -$39.65M-49.4% | ||
| -$56.91M-43.6% | -$48.94M-24.2% | -$47.68M-37.1% | -$41.31M-55.6% | -$39.65M-49.4% | ||
| -$57.31M-43.1% | -$49.4M-23.8% | -$48.06M-36.6% | -$41.69M-50.0% | -$40.05M-49.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Solid Biosciences Inc.'s revenue?
- Solid Biosciences Inc. (SLDB) generated $8.1M in revenue over the trailing twelve months, down 40.6% year over year.
- Is Solid Biosciences Inc. profitable?
- Solid Biosciences Inc. is not currently profitable: it reported a net loss of $191.8M over the trailing twelve months, a -1062.3% net margin.
- What is Solid Biosciences Inc.'s earnings per share?
- Solid Biosciences Inc.'s diluted EPS over the trailing twelve months is $-1.95.
- Where does Solid Biosciences Inc.'s income statement data come from?
- Every line is extracted from Solid Biosciences Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
